1 / 44

Infection Case Presentation

Infection Case Presentation. Dr. Fusun ALATAS Eskisehir Osmangazi University , The Medical School , Department of Chest Diseases. 39 years old , housewife Complaints : Cough , stomach achse , nausea , weakness , dyspnea , sweat History :

emlyn
Download Presentation

Infection Case Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. InfectionCasePresentation Dr. Fusun ALATAS Eskisehir Osmangazi University, TheMedicalSchool, Department of ChestDiseases

  2. 39 yearsold, housewife Complaints: Cough, stomachachse, nausea, weakness, dyspnea, sweat History: Thepatient had cough, weakness, sweatcompliantsforonemonth, but suddenstartedstomachachse, nauseaanddyspneawereaddedonedayago. Smoking:No Asbest exposure: Environmentalexposurefor 24 years

  3. PhysicalExamination : BP: 110/70 mmHgPulse: 108/min RR:18/minFever: 36.7oC RespiratorySystemExamination: VT andsonoritywasdecreased at rightbasal Crackles at rightmiddlezoneandbreathingsoundsdecreased at basal

  4. Laboratoryfindings: Leucocytes: 10900 mm/3Hb: 13 gr/dlPlt: 135000 mm/3 Sed: 94 mm/h CRP: 27 mg/dl T.protein: 4,1 gr/dl, Alb: 2,2 gr/dl ABG: PaO2: 65 mmHg, PaCO2: 27mmHg O2Sat: %91 pH: 7,51 ECG: Sinustachycardia

  5. Question 1: What is yourdiagnosisforthiscase? A- Lungcancer B- BOOP C- Pulmonarylymphoma D- Pulmonaryembolism E- Parapneumoniceffusion

  6. Question 2: What do you plan fordiagnostictests ? A- BT, thoracentesis B- Ventilation-perfusionscintigraphy, thoracentesis C- Bronchoscopy D- PET-BT E- Dynamic spiral BT, thoracentesis, d-dimerlevels

  7. d-dimer : 555,8 ug/dl

  8. Thoracentesis: Serousfluid PleuralfluidSerum LDH (U/L) 327 403 Protein (gr/dl) 3.1 4.1 Albumin (gr/dl) 1.8 2.2 Glucose (mg/dl) 72 85 Exudate Slide: PMNL

  9. Question 3: What is yourdiagnosis at this moment? A- Lungcancer + pulmonaryembolism B- Pulmonaryembolism C- BOOP D- Pulmonarylymphoma E- Parapneumoniceffusion + pulmonaryembolism

  10. D- dimer No of CasesSensitivitySpecificity NPV (CI 95%) (CI 95%) (CI 95%) ClassicELISA 1579 97-99 40-46 96-99 Vidas DD 639 98-100 40-49 98-100 ClassicLatex 364 87-96 48-62 83-94 Simplired 1317 82-91 65-71 94-97 Liatest 386 98-100 29-41 96-100

  11. Conditionscauseincreasedlevels of D-dimer • Patients in intensivecareunits • Patients at post-operativeperiod • Peripheralvesseldisease • Cancer • Inflammatorydiseases • Elderlypatients • Trauma Kelly J. ArchInternMed.162;2000

  12. Dynamic spiral BT Diameter of mainpulmonaryartery: app. 24 mm Diameter of rightmainpulmonaryartery: app. 15 mm Diameter of leftmainpulmonaryartery: app. 12 mm Fillingdefectcompatiblewithemboluswasobserved in upperlobeposterordistalbranch of rightlung

  13. Riskfactors • Acquired: • Age • Prolongedimmobilization / trauma / surgery • Cancer • Previous VTE • Comorbidities /obesity • Pregnancy/ Postpartum • Oralcontraceptive • Central venouscathater • Antiphospholipid antibodies • Hyperhomocysteinemia • Longtravels • Hereditary: • FactorV Leiden • ProtrombinG20210 • Deficiency of protein C • Deficiency of protein S • Deficiency of antithrombin III

  14. SLE + APS+ steroidusagewerepresent in patient’shistory. Congenital risk factorwas not determined. Thetreatment of patientwaschangedto LMWH duetocoumadinusagehistory. Increaseddyspnea, purulentsputumandfever (38oC) wereobserved at thirdday of hospitalization.

  15. Sputum; Gram stain: Increased PNL, ARB: (- ) Gram stain: Few gram positivecoccusand gram negativebacillus ARB: (-) Gram stain: Few gram positivecoccusand gram negativebacillus ARB: (-) Sputumculture: negative Bloodculture: negative Pleuralfluidculture: negative

  16. Question 4: Ifthepatientwasdiagnosed as PTE andacceptedhavedepressedimmunity, whatwouldyournext plan? A- Begin3rd generationnonpseudomonalcephalosporintreatment, clinicalandradiologicalfollow-up • B- Begin 2nd generationcephalosporin,performtransthoracicbiopsy • C- Begincarbapenem, follow-uppleuralfluidwithserialthoracentesis • D- Performfiberopticbronchoscopytoevaluateintrabrochialareaandtake sterile samplethenbegincarbapenem+amicasin. Plan transthoracicbiopsy at thesame time. • E- Evaluatethepleurawiththoracoscopyandsamplingifrequired, insert thetubeandbegin 3rd generationnonpseudomonalcephalosporintreatment

  17. FOB findings: Anypathologicalchangeswere not observedexceptextensivepurulentsecretion in tracheaandrightbronchus. Carbapenemtreatmentwasstarted. Sterile BAL: Gram stain: Gram positivecoccus, rare gram negativebacillus ARB: (-)

  18. Sterile BAL culture : Nocardiaspp TMP-SMT wasaddedtotreatment. Carbapenemandamikacinwerestopped at 10thday of treatment.

  19. 3rd day of treatment

  20. 20 thday of treatment

  21. Pretreatment 20 thday of treatment

  22. Pretreatment 20 thday of treatment

  23. Pretreatment 20 thday of treatment

  24. Pretreatment 20 thday of treatment

  25. PulmonaryNocardiosis • Bacterias of Nocardiaspeciesarepresent in nature, soilandwaterwidespread • Mostlysaprophyte • EdmondNocardwasfirstdescribed in animals in 1888 • Firstdescribed in humansbyEppinger in 1890 Ambrosioni J. Infection 2010; 20

  26. Risk Factors Decreasedcellularimmunity has an important role Transplantationpatients Patientswithleukaemia PatientswithAIDS Patientswhoreceiveprolongedtreatmentswithcorticosteroidsorcytotoxictherapywereunder risk. Cases in normal hostwerealsoreported. Clark NM.Am J Transplant. 2009;9 Suppl 4:S70-7 Martinez R. CurrOpinPulmMed 2008; 14: 219-27.

  27. Thepresentation of pulmonarynocardiosis is highlyvariablebothclinicallyandradiographically. Acute, subacuteandchronicinfectionswithNocardiaspp. havebeenreportedtocause a variety of nonspecificmanifestations, such as anorexia, cough, pleuralpain, dyspnoeaandhaemoptysis. Theincidencewaslowduetomimicedbymalignantandgranulomatousdiseases Conant EF.J ThoracImaging. 1992 ; 7:75-84. Ambrosioni J. Infections 2010; 20

  28. Chestradiographsdemonstrate a variety of findings, such as lobarinfiltrates, cavitation, nodules/massandpleuralinvolvement. Buckley JA. J ComputAssistTomogr 1995; 19: 726-32

  29. Specimens • Bronchialwashing • • BAL • • Sputum • • Abscesses • • Wounddrainages • Tissues • Cerebrospinalfluids Brown –Elliot BA, et al. ClinMicrobiolRev 2006; 19: 259-82.

  30. Theorganism is weaklyacid-fast, but this is usuallylost on subculture. A modifiyeZiehl-Neelsenstain is bestfordemonstratingnocardia. Growth of theorganism in culturemaytake 2-4 weeks Theusage of moleculartechniqueslike PCR arerestricted at the moment

  31. Treatment Therapy is recommendedfor a minimum of 6 weeks, althoughrelapsesoccurlessfrequentlyiftreatment is continuedto 12 weeks. TMP-SMZ (TMP first 4 week 15mg/kg/d, 5 month 10 mg/kg/d) Imipenem4 x 500 mg + Amikacin 1 gr/d Ceftriakson 2 gr/d + Amikacin 1 gr/d Linezolid 2 x 600 mg po • Ambrosioni J. Infections 2010; 20 • Türk Toraks Dergisi 2009; Cilt 10. Ek 5. Vol 10: Suppl 5.

  32. Prognosis The mortality rates were 41% for PN and 64% for disseminated nocardiosis; when Nocardia disseminated to the central nervous system, the mortality was 100%. Martinez R. Respirology 2007;12: 394-400

  33. Masslikeconsolidation Pulmonaryactinomycosis Pulmonarynocardiosis • Pulmonarylymphoma Pulmonaryaspergillosis BAC Lipoidpneumonia

More Related